Development of infant botulism in a 3-year-old female with neuroblastoma following autologous bone marrow transplantation: potential use of human botulism immune globulin.

Abstract

Infant botulism is a rare disease caused by the release of toxin produced in the intestinal tract by Clostridium botulinum. The disease primarily affects infants under 1 year of age. We report a 3-year-old child with stage IV neuroblastoma who developed symptoms of progressive motor weakness, bulbar palsy and respiratory failure 42 days after autologous BMT. The diagnosis of infant botulism was established by identifying botulism toxin in the stool. Human botulism immune globulin (HBIG) was administered. Following the diagnosis, the patient made significant recovery over the next 7 weeks and was successfully extubated from mechanical ventilation. However, her neuroblastoma eventually recurred and she subsequently died of progressive disease. Although the etiology of the development of infant botulism in this case following autologous BMT still remains unclear, alteration of the intestinal microbial environment from gut sterilization and laminar airflow room isolation or, alternatively, immune suppression during pre- and post-autologous BMT and activation of endogenous spores may have contributed to the development of this disease. The use of HBIG in children with botulism over 1 year of age may be beneficial.

• Authors: W P Shen, N Felsing, D Lang, G Goodman, M S Cairo
• Journal: Bone marrow transplantation (Bone Marrow Transplant) Vol. 13 Issue 3 Pg. 345-7 (Mar 1994) ISSN: 0268-3369 [Print] England
• PMID: 8199579 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Immunoglobulins
• botulism immune globulin

Topics

• Bone Marrow Transplantation (adverse effects)
• Botulism (drug therapy, etiology)
• Child, Preschool
• Clostridium botulinum
• Female
• Humans
• Immunoglobulins (therapeutic use)
• Neuroblastoma (therapy)
• Transplantation, Autologous